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Meeting Purpose:   
 
To discuss an operational research study on adolescent health and cervical cancer 
prevention including HPV vaccines, to help support countries that have already made, 
or will soon make a policy decision to introduce the HPV vaccine.  
 
Background: 
 
The Global Immunization Vision and Strategy (GIVS) of WHO and UNICEF calls for 
reaching broader populations with vaccines by extending immunization programs to all 
age groups. Adolescents typically have little contact with health services, particularly 
for immunization programs. Since new HPV vaccines target adolescent girls, the 
introduction of HPV vaccines may provide an opportunity for adolescents to engage 
more with health services. This may create openings to offer more than vaccination, but 
a package of adolescent health services that includes information, sexual and 
reproductive health education, and adolescent health interventions. To better understand 
the policy and programmatic issues related to delivering HPV vaccines as part of 
comprehensive adolescent health services and for cervical cancer prevention, and as 
stated in the WHO publication " Preparing for the introduction of HPV vaccines: policy 
and programme guidance for countries" (http://www.who.int/reproductive-
health/publications/hpvvaccines/text.pdf) a study is proposed. 
 
With the recent adoption of resolutions by the 48
th
 Directing Council of the Pan 
American Health Organization on adolescent health and on comprehensive cervical 
cancer prevention and control, the region of the Americas has been given a political 
mandate to improve adolescent health services and cervical cancer prevention.  Thus, an 
operational research study to assess the feasibility, acceptability, cost and means for 
service delivery and monitoring adolescent health services, including cervical cancer 
prevention and HPV vaccines would help support the implementation of these two 
resolutions.   And as there are several countries in the Americas initiating or considering 
the introduction of the HPV vaccine, the timing for such a study is appropriate.  A 
meeting of potential study collaborators is proposed to discuss the proposal for an 
operational research study and to refine and adapt the study objectives and protocol.  
 
Meeting objectives:  
 
1. To share information on country programs for adolescent health, sexual and 
reproductive health, cervical cancer prevention and HPV vaccine introduction. 
 
2. To present the proposed WHO adolescent health package, in relation to sexual 
and reproductive health and cervical cancer prevention; and to discuss how the 
package could be adapted and delivered, in relation to current adolescent health 
services in countries. 
 3 
3. To discuss the proposed operational research study to assess the feasibility, 
acceptability, cost and means for service delivery and monitoring of adolescent 
health services, including cervical cancer prevention and HPV vaccines. 
 
4. To define criteria for participating countries and study sites, collaborating 
research centers and researchers.  
 
5. To develop a work plan for the operational research study, for each participating 
country. 
 
Expected Outcomes of the Meeting: 
 
1. A work plan for adaptation and development of the operational research study 
that will commonly be applied in all participating countries. 
 
2. A work plan to implement the operational research study, for each participating 
country.  
 
3. A suggested principal investigator for each country, and designated country 
steering research committee. 
 
Discussing the project to meeting participants: 
 
The new HPV vaccine: an opportunity to improve adolescent’s health services 
 
Representatives from several organizations (PAHO, WHO, UNFPA-Mexico, Center on 
Equity and Reproductive Health, Ministry of Health Mexico –CERH- and the office on 
Prevention and Control of HIV-AIDS-Mexico) discussed the importance of this meeting 
that will allow participating countries the opportunity to share initiatives on the 
introduction of the HPV vaccine and the ways in which introducing the vaccine can 
improve health services for adolescents in four countries in the region of Latin America 
and the Caribbean (Colombia, Peru, Panamá y México). The meeting would give 
participating countries the opportunity to work as a group among different organizations 
and across several programs (immunization, prevention of cervical cancer, reproductive 
and adolescent health). 
 
The seminal idea of using the HPV vaccine to offer health services to adolescents came 
from the finding that adolescents tend not to access health services. In places where 
there is access to specific packages for adolescent health, providers may not implement 
them for several reasons (e.g. they do not know these packages are available, they do 
not perceive adolescents as a group at risk, and they have concerns about the legal 
implications of needing informed consent from parents of minors before they offer any 
health service). The groups from participating countries in this meeting are either 
considering the introduction of the HPV vaccine at the national level or have already 
done so and aim to expand the package of services.  
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The objective of this meeting was to discuss the feasibility of introducing the HPV 
vaccine in combination with a comprehensive package of adolescent health services and  
assess the strategy via a research protocol that follows an operations research  (OR) 
methodology. 
 
The HPV vaccine as a key tool to prevent cervical cancer 
 
The current project is based on the scientific evidence gathered to date on the 
effectiveness of introducing the HPV vaccine to help prevent cervical cancer. This 
evidence and the programmatic guidelines to introduce the vaccine are described in the 
“green guide”, a document drafted by WHO, UNFPA and PAHO entitled “Preparing 
for the introduction of HPV vaccines: policy and programme guidance for countries” 
(see Sharepoint, guide HPV-WHO). 
 
HVP infection is the leading cause of cervical cancer. In most women, the infection 
disappears but chronic infection of some of the HPV genotypes can produce cellular 
changes in the cervical uterine region. Industrialized countries have been successful in 
reducing the death rates attributed to cervical cancer with integrated programs that 
combine: 1) information and education to women regarding the disease and ways to 
prevent it; 2) screening; 3) diagnosis and treatment; and 4) palliative care. Introducing 
the HPV vaccine could strengthen these programs by preventing the infection by the 
HPV virus. There are two vaccines currently available: Gardasil and Cervarix that offer 
protection against four HPV strains and are administered in three doses. The vaccine is 
more effective when it is administered prior to the initiation of sexual activity.  
 
Introducing the HPV vaccine, unlike other vaccines, creates important barriers due to 
factors such as its high cost and access to the target age group. First, introducing the 
vaccine requires coordinating different programs and institutions including vaccination 
programs, cervical control programs, overall health system delivery and the Ministry of 
Education, among others. The decision to introduce a vaccine must be based on the 
burden of disease, its cost-effectiveness, sustainability and, if the country in question 
has the resources and infrastructure needed to introduce it. The groups from each 
participating countries will have to define the feasibility of introducing the vaccine in 
their context, the strategy they will need to supply the vaccine. Important considerations 
include vaccine introduction (via health education campaigns or  through schools, 
defining the appropriate target population and, if it is feasible, carrying out a “catch-up” 
For adolescents who have not previously been linked into the health system. Legal 
aspects such as informed consent and whether the vaccine would be obligatory must be 
considered together with other factors such as the developmental stage of adolescents.  
 
Comprehensive package of adolescent health services 
 
WHO suggests we capitalize on three points in time during which the HPV vaccine 
is/could be administered in order to offer a comprehensive package of health services or 
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a “plus” package for adolescents. WHO carried out an extensive literature review and 
designed a “menu” of choices that could be included in such a package (see Table 1 and 
Sharepoint documents “WHO ADO HPV Lit Review Report 2008 11 14 FINAL” and 
“HPV Intervention Package for Adolescent Health”)  
 
The types of components that could be included in the package are: screening (e.g. 
anemia, vision), delivery of information (sexual and reproductive health, HPV, 
nutrition), service provision (counseling, vouchers, referrals to other health services) 
and delivery of supplies (e.g. Vitamin A, mosquito nets, vaccines such as hepatitis B 
and tetanus). The contents of the package may vary according to the needs of each 
country as well as the most appropriate target population to be included in a planned OR 
study. 
 
Table 1.  Menu of options for a comprehensive package of health services for 
adolescents  
Category 
Intervention 
Definition  
Menu of complementary 
interventions 
Screening  Test or screening for 
diseases or disabilities 
• Anemia screening  
• Schistosomiasis screening  
•  Visual screening (in appropriate 
contexts)  
Information 
provision  
Delivery of interventions 
based on information, 
included in information 
sessions, skill building, 
pamphlets.  
• Information on nutrition  
• Information on Sexual and 
Reproductive Health   
• HPV information  
• Information on tobacco and 
alcohol prevention  
Services Referral to other health 
services, counseling, 
treatments  
• Referral to “vouchers” for health 
services (including SRH).   
• Referral to visual screening  
• Referral to  delivery of 
iron/folate supplements  
Delivery of 
supplies 
Supplies, direct provision 
of basic products or 
increased access to basic 
products 
 
• Antihelmintics (transmitted by 
contact with floor) 
• Antihelmínticos 
(schistosomiasis)   
• Mosquito nets for prevention of 
malaria  
• Vitamin A  
Vaccines The vaccines identified to 
complement the 
administration of the HPV 
vaccine (primary or 
Tetanus/ Diphteria booster dose  
Hepatitis B ( booster) 
Costa Rica ( booster ADO P) 
Meningococal (only to specific groups 
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booster) for this age group  and high risk areas in LAC) 
Typhoid (only for outbursts) 
Rubeola (SR booster)  
 
Introducing the HPV vaccine and the comprehensive package of adolescent health 
services in the region of Latin America and the Caribbean: a strategic opportunity  
 
The LAC region has the largest cohort of young adults aged 10-24 and the most 
inequitable distribution of income in the world.  Most of these young people come from 
low income strata and have a high prevalence of unwanted pregnancies. Implementing 
this project constitutes a strategic opportunity since the political climate seems ripe for 
it. In 2008, El Salvador hosted a regional meeting that convened presidents and key 
stakeholders who drafted a youth plan aimed at improving the sexual and reproductive 
health of adolescents for the next ten years. The HPV vaccine could constitute an 
important opportunity to address all forms of inequality in the region. 
 
In May of the same year, 2008 a meeting was organized in Mexico to discuss the state 
of the art and recent developments in the field of the HPV vaccine (“Towards the 
prevention and comprehensive control of cervical cancer”– see Sharepoint, document 
HPV_MEX Declaration).  
 
A few months later in September 2008, the organizing committee from PAHO and 
WHO drafted a resolution entitled “Strategy and regional action plan for the prevention 
and control of cervical cancer” (see Sharepoint, document CD48 R10 Cancer 
cervicouterino-Esp). During this meeting, the committee called the member states to 
introduce the HPV vaccine if the price was feasible and financing became sustainable. 
PAHO offered technical assistance to strengthen integrated cervical cancer programs 
and support decision makers who showed an interest in introducing the vaccine. 
 
Presentations on the current situations in participating countries with respect to 
adolescent health, the HPV vaccine, and opportunities for introducing a 
comprehensive adolescent health package 
 
Each country presented their country profile, the way their health care system was 
organized, current status of adolescent health and an update on the HPV vaccine. For 
more detailed information you can access the power point presentations in Sharepoint.   
 
Mexico – Dr. Patricia Uribe (National Center on Equity and RH-MOH) 
 
Context and adolescent needs: The Federal MOH has several programmatic areas that 
oversee adolescent health. The National Center on Equity and RH (NCERH) is in 
charge of the cervical cancer program and currently does not have the technical 
expertise or experience working with adolescent health. The most common health 
problems among adolescents in Mexico include: early initiation of sexual activity  (20% 
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start between 15-19 years); pregnancy at an early age (18 years in rural areas); and a gap 
between knowledge and practice.  For example, n spite of having high levels of 
knowledge of contraceptive methods, 90% report having had their first sexual 
experience without protection. Other problems include the increasing incidence of 
sexually transmitted infections and high rates of dating violence in this age group. The 
MOH has designed youth friendly services to avoid the barriers associated with 
traditional services such as lack of knowledge of bureaucratic procedures from the 
patient’s perspective, lack of knowledge of legal aspects of service delivery to minors 
from the provider’s perspective, office hours that are  not convenient to adolescents, 
among others. As is common in most countries, women are more frequent users of 
health services than men and tend to seek care for issues regarding maternal health. 
 
Cervical cancer context: In Mexico, cervical cancer is still the leading cause of  cancer-
related death in the poorest areas of the south that border with Central America (breast 
cancer is the leading cause of death at the national level). In these areas, cytology 
coverage is low. The National Institute of Public Health of Mexico carried out a pilot 
study on strategies aimed at decreasing the prevalence of cervical cancer. Based on their 
initial findings and following their technical advice, in 2008, the NCERH selected the 
125 communities (“municipios”) with the lowest level of human development indexes 
in the country and began an HPV vaccine program for all adolescent girls between 9 
and 12 years. Due to budgetary restrictions, they were unable to include a larger number 
of communities. It has been shown that these communities have the highest risk of 
acquiring cervical cancer. As part of the intervention, DNA testing for cervical cancer 
was also offered to women. In 2009, the MOH plans to administer the HPV vaccine and 
DNA testing to more communities throughout the country. The intervention will stress 
the need to carry out the Papanicolau test as well as increase coverage of DNA testing at 
the national level. Similarly, the MOH plans on strengthening the quality of diagnosis 
and treatment that is currently offered free of charge to all women in Mexico. The HPV 
vaccine is currently administered thru the school system and community centers via a 
health education marketing campaign. While some challenges remain, the vaccine has 
been very well accepted and key stakeholders have the political and social will to carry 
out this project successfully. 
 
The HPV vaccine: In 2008, the MOH purchased the HPV vaccine for $ 436.47 pesos 
per dose (current exchange rate is 13.5 pesos per $1 USD). The national health security 
system later bought it at a lower price of $ 327.00 pesos per dose and the Mexico City 
MOH was able to buy it at $ 21.00 USD as greater competition among the 
pharmaceutical companies that manufacture the vaccine arose. At the beginning, the 
vaccine was administered in the following schedule of 0, 2 and 6 months. Researchers 
are currently trying to define the feasibility of administering it at 0 and  2 months (for 9 
yr olds) and at 60 months (for 15 yr olds). This schedule is based on one implemented 
successfully in Quebec, Canada. The period of time between the second and third dose 
will provide ample time to determine the need for administering the third dose.  
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Panama – Dr. Yadira Carrera (Ministry of Health) 
 
Context and adolescent needs: As in the rest of the LAC region, Panama has a high rate 
of adolescent pregnancy (18%). The Ministry of Health and Social Development of 
Panama has health programs targeted for adolescent and recently launched a teen 
pregnancy prevention program in collaboration with UNFPA (2006-2008). The country 
also has a comprehensive adolescent health program. Nevertheless, this program has 
access barriers such as lack of space for teenagers seeking medical care and provider 
training needs so that they can offer care to adolescents accompanied by their parents. 
In addition, the country has to face the challenge of the opposition from the Catholic 
Church towards the use and distribution of contraceptive methods.  
 
Context of cervical cancer: HPV infection is the fifth leading cause of morbidity in 
Panama. At the national level, cervical cancer is the second leading cause of death 
followed by breast cancer. Most cases are concentrated in rural areas. The country has a 
cervical cancer screening program which is especially difficult to implement in rural 
areas due to the distrust associated with Pap tests among the population. The country 
needs to reinforce existing training among providers, health education campaigns as 
well as train laboratory personnel and develop adequate technical infrastructure to carry 
out screening tests. 
 
The HPV vaccine: In October 2008, Panama added the HPV vaccine to their 
comprehensive immunization program. The vaccine is offered free of charge to 10 year 
old girls (10 to 10.11 months) in three doses. The vaccine will be offered through the 
public health system and in MOH clinics. They have developed the service provision 
delivery system for the vaccine.  
 
Peru – Dr. Lourdes Palomino (Ministry of Health) and Dr. Mario Martínez 
(PAHO) 
 
Context and adolescent needs: In Peru, one fifth of the population is of adolescent age, 
living in cities, 60% are migrants from rural areas and 20% have low levels of 
schooling. Rural areas have the highest rates of adolescent pregnancies. Contraceptive 
coverage is low, STI transmission is high and the country has high rates of gender based 
violence, including sexual violence. The MOH is currently undergoing health care 
sector reform and moving toward access to universal health care. The current strategies 
aimed at adolescents include sexual and reproductive health together with mental health 
services that are offered throughout 700 youth friendly clinics where adolescent access 
services using a “carnet.” As part of these youth friendly services, the MOH has also 
included social and personal skill building that allow adolescents to act as community 
leaders in a peer-based service delivery system. 
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Context of cervical cancer and the HPV vaccine: Dr. Martínez stressed the benefits that 
vaccines have in the epidemiology of diseases. Peru has a high rate of cervical cancer, 
especially in rural areas with extreme poverty that are difficult to access such as the 
jungle region. The HPV vaccine has not been introduced in Peru yet although the MOH 
carried out a pilot study with an international NGO (PATH) in three sites (Piura, 
Ayacucho and Ucayali) with the aim of assessing a future implementation strategy that 
measures acceptability among the population and among providers and determines the 
resources that will be needed and if the HPV vaccine constitutes a health priority in 
Peru. Girls enrolled in school participated in the study once their parents had given 
informed consent. The vaccine was administered in three doses at 0, 2 and 6 months. 
Over 1,000 girls received the vaccine and large coverage was achieved. The cost per girl 
for three doses was $90 USD; this price included total costs such as transporting the 
vaccine, provider’s salaries, etc.).  
 
Colombia - Sonia Bedoya (Government Province of Medellin) and Marion Piñeros 
(National Cancer Institute) 
 
Context and adolescent needs: In Colombia, 13.7 % of women between ages 15 and 19 
report having their first sexual relationship before they reach 15 years; 80% of women 
in that same age group currently do not use a contraceptive and only 38.2 % have ever 
used a contraceptive method. These figures illustrate an important unmet need for 
family planning methods in Colombia. The MOH is actively working to strengthen 
adolescent health programs and facilitate access to services and methods. 
 
Context of cervical cancer: Cervical cancer is the leading cause of death in Colombia. A 
National Health Plan 2007-2010 was drafted and one of its goals is to reduce the 
mortality associated to cervical cancer. Early screening and detection in the country is 
acceptable (77% in the last 3 years) but they still have to work on coordinating 
screening, detection and treatment. Colombia has considered carrying out a pilot study 
focusing on the areas with the highest cervical cancer prevalence among the most 
vulnerable groups. A prior study documented the most common HPV strains associated 
with cervical cancer (16 and 18) were found to be most prevalent. The most aggressive 
forms of HPV were found among women between ages 15 and 30 and a second peak 
was found among women between ages 40 and 50 (often associated with sex outside of 
marriage).  
 
The HPV vaccine: The Colombian government supports the potential introduction of the 
HPV vaccine. The factors they are taking into account include: burden of disease; cost-
effectiveness of the vaccine; and, logistical and financial sustainability. Because of the 
current political conditions in the country, the government has a long list of unmet 
health needs. However, each province has its own MOH and the discretionary power to 
allocate resources according to need and to add health priorities to the National Health 
Plan. The following ethical considerations will be taken into account when designing 
the study methodology: will they select all girls or will they select particular 
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communities and administer the vaccine to all girls? How will they address the social 
reaction and doubts surrounding the vaccine’s efficacy? How will they address the 
controversy of the booster dose? How will they design future screening programs? How 
will they be able to increase parental consent for minors? How will they address 
continuity of the vaccine for future cohorts? Researchers attending the meeting agreed 
that an operations research methodology may help clarify some of these questions. 
Colombia is planning on packaging the HPV vaccine as a strategy to prevent cervical 
cancer and not as a vaccine to prevent STIs. The MOH is also interested in including the 
vaccine as part of a comprehensive health package for adolescent health. 
 
Lessons learned from two countries with experience introducing the HPV vaccine 
Canada – Shainoor Ismail 
 
Current program: The incidence of cervical cancer in Canada is decreasing. In 2008, 
most provinces in the country have an HPV vaccine program and they are currently 
administering Gardasil. They administer the vaccine to girls between ages 9 and 13 
(before the beginning of sexual activity) in three doses (0, 2 and 6 months) as part of a 
cervical cancer prevention program. It is offered in schools as a strategy that has proven 
highly effective in Canada where acceptability is quite high. The vaccine was first 
introduced with a social marketing campaign that used pamphlets, websites and other 
dissemination materials. They determined that in order for the project to be cost-
effective, coverage had to be of at least 70%, a goal that was reached. Researchers have 
noted the importance of carrying out a project that measures the impact of the 
intervention, something they anticipate will yield positive results in the long term. 
 
United Kingdom - Loretta Brabin 
 
Current program: Since September 2008, the United Kingdom has had an HPV 
immunization program. Cervarix is administered in three doses (0,1 and 6 months) to 
girls between ages 12 and14 who are attending school. A catch-up program was 
designed and the vaccine will be offered for three years to adolescents up to 18 years. 
The vaccine was introduced together with a social marketing campaign stressing the 
message that it prevents cervical cancer. 
 
Prior challenges: Before the program was introduced, a study was carried out among 
3,000 girls aged 12-13 to assess the feasibility and acceptability of the vaccine. Results 
were quite favorable for both. Initial challenges included opposition from the Catholic 
Church who opposed the vaccination scheme arguing they were “experimenting” with 
girls. Another aspect that was debated was the finding that nurses in schools were not 
always able to respond adequately to parents’ concerns especially when dealing with 
those who opposed the vaccine. All these challenges were successfully addressed and 
they ended up not having a negative effect on the overall acceptance of the vaccine. 
Most of the questions put forth by parents had to do with side effects, risks associated 
with the vaccine and if it would promote sexual promiscuity among the young girls. 
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Another challenge included informed consent from the parents: nurses were not 
comfortable administering the vaccine without parental consent and once parents found 
out their consent was not needed; this made them more cautious about giving their 
consent. Maintaining the adolescent’s confidentiality was also an important issue. Those 
parents who initially opposed the vaccine and later gave their consent posed a 
methodological dilemma since girls who joined the program later were not able to 
follow the same treatment protocol. The coverage for the first dose was quite high at 
83%. As part of the program, women aged 25 and older were reminded to seek 
screening for cervical cancer. The experience from the United Kingdom illustrates that 
despite initial concerns, the vaccine was highly acceptable and feasible to implement. 
Coverage that does not reach traditional immunization programs is still high. However, 
keeping girls aware and well informed is an ongoing challenge. In sum, the provision of 
the HPV vaccine constitutes a good starting point to design a more structured program 
around the sexual and reproductive health needs for adolescents. 
 
Discussion: 
 
The prior presentations generated a lively discussion about the challenges that lie ahead 
for countries wanting to implement the HPV vaccine. The following issues could help 
countries develop their operations research protocol: 1) schools are key sites to offer the 
vaccine as part of a school health program (for those countries where such a program is 
in place); 2) countries must reach a consensus on the way in which they plan to 
implement the social marketing campaign and define the key messages regarding the 
vaccine they wish to convey. For example, the United Kingdom promoted the program 
as a way of preventing cervical cancer while other countries may chose to focus on a 
campaign about sexual and reproductive health and STI prevention among adolescents. 
 
Operations research (OR): proposed methodology 
 
To inform the countries’ development of OR studies to test the HPV vaccine within a 
comprehensive adolescent health package, Estela Rivero, researcher and professor from 
El Colegio de México, provided a review of OR addressing basic concepts relevant to 
design formative research and future interventions (The content of her presentation can 
be found in Sharepoint, document “Introduction to OR.”)  
 
The WHO’s proposal for carrying out OR was discussed by Dr. Garrett Mehl (see 
Sharepoint, document “Design- Adolescent study -HPV”). For the OR project put forth 
by WHO we need to take into account the three following questions:  
 
• What is the added value of administering the HPV vaccine as part of other 
specific health interventions for adolescents including sexual and reproductive 
health services? 
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• What are the repercussions of administering the HPV vaccine in an adolescent 
“plus” package as part of the HPV immunization program (catch up, coverage, 
etc.)? 
• What is the added value of including the HPV vaccine as part of the national 
program of cervical cancer control?  
 
The group’s hypotheses are that offering the “plus” package together with the HPV 
vaccine will have a positive effect on knowledge and a reduction of sexual risk 
behaviors among adolescents; that introducing the HPV vaccine together with the 
“plus” package will not have a negative effect on the use, uptake or coverage of the 
vaccine in the services offered to school aged children; and, that providing the HPV 
vaccine will increase the use of screening services for cervical cancer from mothers of 
the girls that were previously given the HPV vaccine. 
 
The project will have three phases. In phase one, components that will be included in 
the package will be defined, including the HPV vaccine. During phase 2, OR studies 
that measure the feasibility, acceptability and determines aspects of monitoring, 
evaluation and cost of the package will be conducted. Phase 3 will include a more 
ambitious project that includes a case control methodology. The specific aspects of each 
stage were described in the power point presentation. 
|
Figura 1. Las tres etapas del proyecto para la introducción de la vacuna contra el VPH y el 
paquete integrado.
 
Discussion:  
 
After the methodological discussion regarding the OR projects, participants posed 
questions regarding the feasibility of evaluating the impact of the intervention in terms 
of a measurable behavioral change among the girls that received the HPV vaccine. They 
concluded that based on some of the components of the package, it would be possible to 
measure behavioral changes while noting that in the case of sexual and reproductive 
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health the observable changes would be in terms of levels of knowledge. Participating 
countries expressed some doubts regarding the best way of implementing the “plus” 
package and the ethical issues that arise when budgetary restrictions do not allow them 
to implement the package to all adolescents. All agreed that the HPV vaccine constitutes 
a strategic opportunity to improve the coverage and use of health services among 
adolescents and it is the task of each country to define their local context and 
implementation mechanisms.  
 
Evaluating the costs of introducing vaccines 
 
Bárbara Jauregui discussed her experience implementing  a PAHO initiative to 
introduce new vaccines entitled ProVac, aimed at strengthening a country’s abilities to 
make evidence based decisions on whether or not to introduce the HPV vaccine. Her 
presentation entitled “Assessing costs in an operations research project” discussed the 
topic of cost-effectiveness in introducing and sustaining new vaccines using the 
following formula:  
 
CEA= Program costs – costs avoided by preventing disease 
_____________________________________________ 
Health benefits (DALYs) 
 
CEA: Cost effectiveness analysis 
DALYs: Disability Adjusted Life Years 
 
For this project, the WHO developed a costing tool kit for health and development 
services aimed at adolescents. This kit could be used to measure the costs associated 
with introducing the HPV vaccine alone and in combination with the comprehensive 
package of health services for adolescents. The kit can be adjusted depending on the 
package of health services available in each country. The ProVac team is willing to 
work together with the WHO to sharemethodologies, field work experiences and assess 
the possibility of integrating tools in the future. 
 
 Preliminary ideas for an OR project in the four countries, challenges and next 
steps 
 
Using a series of questions as a guide, each country drafted a preliminary plan to 
explore the potential components that could be included in the comprehensive health 
package for adolescents in combination with the potential introduction of the HPV 
vaccine and the initial methodological OR design (see presentations in Sharepoint).  
 
Mexico 
 
For Mexico, improving its cervical cancer control program thru the HPV vaccine for 
adolescents is a priority together with an improving cervical cancer diagnosis and 
treatment among women. The Mexico group concluded that it was indeed possible to 
carry out a feasibility study to asses the acceptability of the “plus” package that is not 
currently offered in the new HPV vaccine program. Researchers from Mexico were 
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interested in participating with the other countries in this effort. The challenge would be 
to adapt the package to communities by including the schools, the media and other key 
players. Their main research questions included, among others: 1) Which interventions 
from the “plus” package for adolescents and for women could be combined with the 
HPV vaccine? 2) Are these interventions acceptable among the community and among 
health professionals? 3) Will health care coverage among adolescents increase with the 
increased coverage of the HPV vaccine?  The group from Mexico would like to carry 
out a situational analysis to assess the health needs in communities that could serve as a 
basis for working with local health authorities. While Mexico has an adolescent health 
package, its coverage is more widespread in urban areas. One of the aims will be to 
assses the feasibility of adapting the adolescent health package to meet the needs of the 
most vulnerable communities and those with the lowest human development indices in 
the country. Components of the health package will include information on SRH, family 
planning, gender equity, gender based violence, etc. The final components of the 
package will be determined once the results of the situational analysis are available. The 
country currenty has a vaccination card for adolescents aged 10 to19 years. 
 
For the case of Mexico the intervention would include: adding the “plus” package of 
health care services for adolescents to the HPV vaccine that is currently being 
administered to girls in the poorest 125 communities in the country. More communities 
with low human development indexes could be added if funding becomes available. The 
information and services that could be included in the package could be: information on 
SRH, nutrition, family violence, gender equity, STI and pregnancy prevention. Other 
vaccines could be also administered together with condoms, folic acid and 
contraceptives. 
 
The package will be offered by health promoters (promotores de salud). The group 
mentioned they could join efforts with the cervical cancer program at the MOH to carry 
out the study. The key players involved in the study would be: The National Center for 
the Control and Prevention of HIV/AIDS (Censida), The National Center for the Health 
of Children and Adolescents, the National Institute of Public Health (INSP), health 
caravans from the federal MOH, UNICEF, WHO, Population Council and others. This 
group of experts will design and carry out the pilot phase of the study. In order to offer 
the “plus” package they will need a multidisciplinary team and other partners such as 
the National Institute of Epidemiological Reference and IMSS Oportunidades. They 
will need to hire additional personnel to carry out surveys, do the training, draft data 
collection instruments and analyze data. Next steps include convening an experts 
meeting with key players, define more carefully the components of the “plus” package 
and define the final study methodology. 
 
Discussion: 
 
Following Mexico’s presentation,  unfortunately there was no time for group discussion. 
Nevertheless, the country’s team will have to carefully address some of the topics raised 
during the presentation such as the implications associated with the Mexican MOH 
decision to use a different schedule than the one used and promoted by WHO. Until this 
new schedule (two doses followed by a third booster dose at 60 months) is recognized 
as an internationl standard, the Mexican government and its colleagues will not be able 
to receive WHO funding for its OR study. The latter could be taken as an opportunity to 
seek funding from new donors and seek new research partners which can lead to the 
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approval of this novel schedule and be considered the evidence based medicine needed 
to provide the HPV vaccine. 
 
Panama 
 
Since October 2008, Panama has offered the HPV to girls starting at 10 years enrolled 
in school. The OR proposed by the country team would use an experimental design by 
offering the “plus” package in combination with the HPV vaccine. Given that the basic 
adolescent health package offered in Panama already includes a series of screening tests 
for vision, hearing, psycho social well being and accident prevention, the “plus” 
element in the package would be to add the HPV vaccine together with 8 additional 
sessions on health education that included topics such as cervical cancer, gender and 
human rights. Panama has several models that could be adapted to the OR methodology. 
The country team also considered adding recreational and sport activities for girls 
receiving the vaccine. The study will compare the “plus” package in combination with 
the HPV vaccine administered to 500 girls vs the “plus” package only administered to 
500 girls conforming the control group. Mothers of girls receiving the vaccine will be 
offered health education sessions that focus on prevention and cervical cancer 
screening, effective communication strategies with their children, family violene, 
women’s human rights, prevention of gender based violence and sexual exploitation. 
The OR study will include a 24 week intervention: on day 0 they would administer the 
HPV vaccine, the first educational session,and a baseline KAP survey. The intervention 
will also include meetings with parents and violence surveillance. On day 30 they will 
administer the second dose and the educational sessions with mothers and girls will be 
given. On day 180 they will carry out the “post” KAP survey to assess change in these 
indicators. The HPV vaccine with and without the  “plus” health package for 
adolescents will be offered in schools. The Gorgas Institute (a local research institute 
with a representative attending the meeting) will offer technical assistance calculating 
the sample size, random selection and implementing the study. The results obtained in 
the KAP study will be used for purposes of monitoring and evaluation. Researchers will 
measure attendance at educational sessions and positive change in reported family 
violence. Keys partners will include: UNFPA, WHO, MOH Panama, Gorgas Institute, 
among others. Country members expressed their interest in inviting local and 
international NGOs that have experience working with adolescents such as the Red 
Cross and the Lions Club. They will convene meetings with these groups to present the 
OR study methodology and will work on a final version of the study protocol. 
 
Discussion: 
 
The country team discussed the selection criteria for the girls who will participate in the 
study. The Gorgas Institute was chosen to calculate the sample. They mentioned they 
would first have to know the coverage of the current health package for adolescents in 
Panama targeted for adolescents between 10 to 19, although they believe it will be 
somewhat difficult to measure real coverage. They concluded that administering the 
HPV vaccine in schools may help strenghten the demand for other health services 
among adolescents. 
 
Colombia 
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The group from Colombia thought it would be feasible to introduce the HPV vaccine in 
the country given that the national government supports this health initiative. They also 
mentioned that some important challenges lay ahead given that no formal agreement has 
been reached. They propose to start implementing the OR project first. Among the 
challenges they anticipate they included: political misgivings due to pressure that will 
be exerted by the pharmaceutical industry; a MOH officials’ hesitation regarding 
purchase of the vaccine; difficulty in accessing girls who live in impoverished or rural 
areas that are often the ones with the highest rates of HPV; coverage of future cohorts; 
and, costs of the vaccine. The Colombian governement is in the process of consolidating 
the vaccination schedule for influenza virus and developing universal access to rotavirus 
and pneumococus. The latter may delay or hinder the approval of the implementation of 
the HPV vaccine. Participants also noted that while the above is worth considering, 
provincial governments do have the autonomy to establish or create additional health 
priorities provided they follow the guidelines dictated by the federal MOH and are 
evidence based medicine interventions (e.g. burden of disese, cost-effectiveness and 
logistical and financial sustainability).  
 
The research questions posed by the group included: 1) How can we attain adequate 
coverage of the HPV vaccine among the population most at risk? 2) How can we 
achieve sustainability given the high cost of the vaccine?  3) How can we improve the 
existing health services for adolescents maximizing the time the provider spends with 
the patient? The group wanted to address two working hypothesis: the introduction of 
the HPV vaccine in combination with the “plus” package will not have a negative effect 
in the curent vaccine coverage; and, the provision of the “plus” package combined with 
the HPV vaccine will improve the access and the service utilization among adolescents.  
 
Currently, there is an adolescent health services program that includes visual and 
anemia screening, growth and development. The “plus” package would add information 
on SRH, the HPV virus and its association with cervical cancer, and prevention of 
gender based violence. The convenience sample would consist of adolescent women 
and the study will be carried out in the province of Medellín in two areas with low 
levels of human development indices. The study will include an intervention arm 
(“plus” package) and a control group (current adolescent health services and the HPV 
vaccine using a social marketing campaign) in each study site. They will offer the two 
options (both in private and in public clinics) thru their adolescent health service 
networks. A careful selection of the population will be needed together with insuring 
the availability of vaccines for future cohorts. The project’s success will depend on 
political will and the possibility of securing funding to purchase the vaccine.  
 
A KAP study will be carried out to measure the effect of the vaccine (including 
knowledge of SRH and HPV and use of health services among adolescents and their 
mothers). Other studies will include a cost-effectiveness analysis and an evaluation of 
the quality of the services being offered. The following institutions will make up the 
working group: health services in the sites selected to carry out the study; the Ministry 
of Social Protection; the Colombian National Cancer Institute; and, the WHO and 
PAHO country offices. They will ask the latter for technical assistance to help with the 
negotiation with local key players (MOH) and provincial governments. Colombian 
researchers are interested in sharing expertise and experiences with other countries in 
the region that have introduced the vaccine and discuss their adolescent health 
programs. Next steps will include involving the Ministry of Social Protection, design a 
 17 
work plan to discuss with the communities that will participate in the study, define 
budgets and implement the project. 
 
Discussion: 
 
Participants raised the question about the need to include the community, local NGOs 
and academic centers once a final methodology is defined. Colombian participants were 
unaware if the federal government would purchase the vaccine although they thought it 
would be up to the provincial governments do so. Medellin, is one example of a 
province who would be willing to purchase it since they already carried out a cost-
effectiveness study.  
 
Another issue that was raised was:  if Colombia has a network of adolescent health 
services, what would be the added value of implementing the “plus” package or the 
HPV vaccine? A possibility mentioned was that of raising awareness of the existence of 
such health services which would in turn increase the demand for services. Participants 
noted that the network of adolescent health services does not have a wide coverage or a 
comprehensive approach to prevention, detection and treatment. By introducing the 
“plus” package and the HPV vaccine, they could improve the quality and coverage of 
available services.  The option of offering the “plus” package in combination with 
another type of vaccine was mentioned, using Hepatitis B as an example. They did 
acknowledge however, that by administering a different type of vaccine, they would 
lose the focus of the project. Researchers mentioned the need to improve current 
screening services for cervical cancer by implementing the “plus” package and the HPV 
vaccine. 
 
Peru 
 
In Peru the HPV vaccine is only administered in private clinics even though the MOH 
has a comprehensive health package for adolescents and a national immunization 
program.  The country team mentioned that it would be feasible to assess the 
introduction of the HPV vaccine and they would be willing to work jointly with other 
country participants. The challenges that lie ahead include: the country has low 
coverage and access to current health services for adolescents; and, there seems to be 
insufficient coordination between the national vaccination program and the life stages of 
adolescents. 
 
The adolescent health package currently available in Peru shares some similarities with 
WHO’S “plus” package. They both have screening for hearing and vision, growth 
charts, psychosocial health and information on SRH. For the study on OR the 
adolescents who are currently receiving the available health package could serve as the 
“control” group. Key players involved in the project would include: the MOH 
(Immunization Program, SRH Program, Epidemiology Division, offices of 
communication and provision of drugs, IRB and a group of external consultants. 
Partners would include, WHO, PAHO, UNICEF, etc. Participants mentioned the need 
to secure technical assistance and sufficient financial resources to purchase the vaccine. 
 
Next steps would include convening a meeting with the MOH to discuss the future 
introduction of the HPV vaccine that would be followed by a social marketing 
campaign, a cost-effectiveness study, establishment of alliances and parterships and 
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technical assistance to distribute the vaccine which would be offered thru the public 
health sector at the national level. The OR project would focus on three areas where the 
vaccine would be administered in schools and in health community centers. The 
research question put forth by participants was: will the “plus” package improve the 
current health services for adolescents available in Peru? The country team mentioned 
they would draft a report with preliminary results and conclusions derived from the 
Mexico City expert’s meeting, design a study methodology and meet with key players 
at the MOH to define a future strategy. Once this is completed, they would present an 
OR research protocol to their local IRB and would seek technical assistance from 
PAHO. The girls who received the HPV vaccine in the year 2008 with the PATH pilot 
test would conform the “control” group and the girls that will receive the “plus” 
package would be the intervention group. They will also assess if the mothers of the 
girls that received the vaccines had their Pap tests. 
 
Discussion: 
 
Participants from Peru questioned the ethical issue associated with forming  a control 
group since by law, all adolescents are eligible to receive health services. They 
mentioned it was questionable not to include them in the intervention arm of the study. 
A few alternatives were discussed, including: design a study where all girls receive the 
package alone and later in time, receive the “plus” package and the HPV vaccine (once 
the vaccine is available in the country). Other questions included if the “plus” package 
had other benefits aside from increasing cervical cancer screening among mothers of 
girls who receive the vaccine. Another possibility could be that the “plus” package 
could also increase adherence to other types of vaccines or improve health, lifestyles, 
and nutrition. The OR study variables should be clarified in order to reach consensus 
with the MOH and to overcome the barriers and resistance the vaccine.  
 
Conclusion and next steps 
 
All country participants expressed their commitment and willingness to move forward 
with the introduction of the HPV vaccine, the “plus” package, and assess the impact of 
these interventions through an OR project in their respective countries. However, it is 
clear that every country has very particular circumstances and is at different stages of 
introducing the vaccine, which in turn raises other challenges and opportunities. For 
example, Mexico and Panama already have a strategy in place and are offering the 
vaccine but will need to consider carefully how best to proceed with the “plus” package. 
All countries will have to think through the best way they could integrate the HPV 
vaccine into their current health services for adolescents. Peru and Colombia on the 
other hand are at the stage of starting discussions with health authorities about the need 
to introduce the HPV vaccine in their health system as well as securing the essential 
funding to purchase it. By the end of the meeting, each country had drafted a 
preliminary OR plan and mapped out next steps. All teams needed to gather additional 
input and consensus from key stakeholders in their respective countries before 
elaborating study protocols.  
 
Next steps: 
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1. Each country will continue working and refining the implementation of the “plus” 
package and post it on the meeting Sharepoint. They will share study instruments, 
experiences and power point presentations; they will use “Elluminate” to facilitate 
follow-up  
 
2. WHO and PAHO will help countries to further develop the study methodology and 
design of OR protocol   
 
3. Garrett Mehl will draft a summary of lessons learned in the meeting  
 
4. WHO and PAHO will draft a publication based on the meeting report, including 
lessons learned and next steps that will be available in Sharepoint and will be open to 
comments from country participants   
 
5. WHO and PAHO have an international and regional task force that can offer 
technical assistance and support in specific areas, such as the designing the cost-
effectiveness study 
 
6. With the aim of serving as a case study, Sharepoint will open a space where countries 
will be able to upload basic information on sexual and reproductive health indicators, 
age of menarche, percentage of indigenous girls, prevalence of cervical cancer and HPV 
vaccine, availability of the HPV vaccine, which will be useful for elaborating their 
country protocols.  
 
 
